Still nowadays, while novel experimental treatments are being tested and other agents have been shown to have high anti-leukemic activity in APL (e.g. arsenic trioxide, anti-CD33 antibodies), the standard recommended treatment for newly diagnosed APL consists of anthracycline monochemotherapy and ATRA.8,9 No other myeloid or lymphoid acute leukemia shows a similar pattern of chemosensitivity to a single agent, and, in fact, polychemotherapy schemes are the standard treatment in all non-APL acute leukemias. The gene discussed is CD33; the disease is acute promyelocytic leukemia.